Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WDB coco CoTSE:7079 -1.28%67 EV-to-EBITDA is 2.28 as of Aug. 31, 2026, which is 76% below its 10-year median of 9.56. GuruFocus rates TSE:7079 with a GF Score™ of 67/100 and a GF Value™ of 円3,585.09 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 515 Healthcare Providers & Services companies, WDB coco Co ranks better than 95.34% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, WDB coco Co's enterprise value is 円2,247 Mil.
WDB coco Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円986 Mil. Therefore, WDB coco Co's EV-to-EBITDA for today is 2.28.
The historical rank and industry rank for WDB coco Co's EV-to-EBITDA or its related term are showing as below:
TSE:7079'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.28 Med: 9.56 Max: 63.11
Current: 2.28
During the past 9 years, the highest EV-to-EBITDA of WDB coco Co was 63.11. The lowest was 2.28. And the median was 9.56.
TSE:7079's EV-to-EBITDA is ranked better than 95.34% of 515
companies
in the Healthcare Providers & Services industry
Industry Median: 10.62
vs TSE:7079: 2.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
WDB coco Co's PE Ratio (TTM) for today is calculated as:
WDB coco Co's share price for today is 円2554.00.
WDB coco Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円271.760.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for WDB coco Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7079 vs VEEV, BTSG, TEM: EV-to-EBITDA Comparison
For the Health Information Services subindustry, WDB coco Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WDB coco Co EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, WDB coco Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where WDB coco Co's EV-to-EBITDA falls into.
WDB coco Co's current Enterprise Value is 円2,247 Mil.
WDB coco Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円986 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WDB coco Co (TSE:7079) has a EV-to-EBITDA of 2.28 as of Aug. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on WDB coco Co. This is 76% below median its historical median of 9.56. Over the past decade, WDB coco Co's EV-to-EBITDA has ranged from 2.28 to 63.11. According to the industry distribution chart, WDB coco Co ranks #24 out of 515 companies in the Healthcare Providers & Services industry, placing it in the top 4.7%.
Is WDB coco Co's EV-to-EBITDA too high?
WDB coco Co's current EV-to-EBITDA of 2.28 is 76% below median its 10-year median of 9.56. Over the past 10 years, this metric has ranged from a low of 2.28 to a high of 63.11. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.62. WDB coco Co's value of 2.28 is 78.5% below this industry median. Based on the distribution chart, WDB coco Co ranks #24 out of 515 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, WDB coco Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WDB coco Co's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, WDB coco Co ranks #24 out of 515 companies for EV-to-EBITDA. This places WDB coco Co in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 10.62. WDB coco Co's value of 2.28 is 78.5% below this benchmark. Historically, WDB coco Co's own EV-to-EBITDA has ranged from 2.28 to 63.11 over the past decade. While the company's 10-year median is 9.56 vs. the industry median of 10.62, WDB coco Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.62, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WDB coco Co's current EV-to-EBITDA of 2.28 is 78.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on WDB coco Co. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WDB coco Co's current EV-to-EBITDA is 2.28, which is 76% below median its own 10-year median of 9.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WDB coco Co stock overvalued right now?
Based on GuruFocus' analysis, WDB coco Co (TSE:7079) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,585.09, compared to a current price of 円2,554.00 — trading 28.8% below its estimated fair value. The current EV-to-EBITDA is 2.28, which is 76% below median its 10-year median of 9.56 and 78.5% below the Healthcare Providers & Services industry median of 10.62. WDB coco Co's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For WDB coco Co (TSE:7079), the current EV-to-EBITDA is 2.28 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WDB coco Co (TSE:7079) Overvalued in 2026?
Based on GuruFocus' analysis, WDB coco Co stock appears to be undervalued.
The current stock price of 円2,554.00 is trading 28.8% below its estimated GF Value™ of 円3,585.09.
GuruFocus considers WDB coco Co to be Modestly Undervalued.
Key valuation signals for TSE:7079:
EV-to-EBITDA: 2.28 (76% below median its 10-year median of 9.56)
GF Value™: 円3,585.09 vs. price of 円2,554.00 (28.8% below fair value)
Industry Position: 78.5% below the Healthcare Providers & Services median (#24 of 515)
No single metric tells the full story. See the TSE:7079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WDB coco Co Ltd is a provider of safety information management for the development of pharmaceuticals and medical devices. Its services include business related to safety information management, preparation of materials related to regulatory application, QC-related work, PMS facility contract support related work, clinical research support/monitoring, and temporary staffing. The company provides Contract Research Organization services for all new drug developments, such as monitoring, safety information, data management, and statistical analysis. It provides support for the development of generic drugs, such as bioequivalence studies and biosimilars, clinical research, and physician-led clinical trials.
67GF Score
Get the complete analysis for TSE:7079
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7079 has been successfully added to your 
